Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

20171,322 citationsJournal Article

Authors

David S. Ettinger · Smilow Cancer Hospital

Douglas E. Wood

Dara L. Aisner · University of Michigan–Ann Arbor

Wallace Akerley

Jessica R. Bauman

Lucian R. Chirieac

Thomas A. D’Amico · University of Michigan–Ann Arbor

Malcolm M. DeCamp · University of Michigan–Ann Arbor

Thomas J. Dilling

Abstract

This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

Topics & Keywords

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the National Comprehensive Cancer Network

Volume 15, Issue 4, pp. 504-535

DOI: 10.6004/jnccn.2017.0050

Field-Weighted Citation Impact: 145.58